Journal
Journal of Thoracic Oncology
Publication Date
9-1-2021
Volume
16
Issue
9
First Page
1582
Last Page
1588
Document Type
Open Access Publication
DOI
10.1016/j.jtho.2021.06.022
Rights and Permissions
Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, Chen C, Ludwig C, Patel M, Nimeiri H, Komarnitsky P, Camidge DR. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. J Thorac Oncol. 2021 Sep;16(9):1582-1588. doi: 10.1016/j.jtho.2021.06.022. Copyright 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Hann, Christine L.; Burns, Timothy F.; Dowlati, Afshin; Morgensztern, Daniel; Ward, Patrick J.; Koch, Martina M.; Chen, Chris; Ludwig, Carrianne; Patel, Maulik; Nimeiri, Halla; Komarnitsky, Philip; and Camidge, D. Ross, "A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC." Journal of Thoracic Oncology. 16, 9. 1582 - 1588. (2021).
https://digitalcommons.wustl.edu/oa_4/1470
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
